Company news

Arcutis Biotherapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis

March 15, 2020

Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communications

March 4, 2020

Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for Late-Breaking Oral Presentation at the American Academy of Dermatology (AAD) Annual Meeting

March 2, 2020

Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis

February 12, 2020

Arcutis Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

February 3, 2020

← Newer news releases

Calls

The 5 newest of 17 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.